Evidence map›Paper›PMID 38725031›Full record

ReviewJournal of nanobiotechnology2024

Cucurbit[8]uril-based supramolecular theranostics.

Dan Wu, Jianfeng Wang, Xianlong Du, Yibin Cao, Kunmin Ping, Dahai Liu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of nanobiotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Dan Wu *Department of Vascular Surgery, China-Japan Union Hospital, Jilin University, Changchun, 130033, People's Republic of China.
Jianfeng Wang *Department of Radiotherapy, China-Japan Union Hospital, Jilin University, Changchun, 130033, People's Republic of China.
Xianlong DuBethune First Clinical Medical College, Jilin University, Changchun, 130012, People's Republic of China.
Yibin CaoCollege of Materials Science and Engineering, Zhejiang University of Technology, Hangzhou, 310014, People's Republic of China.
Kunmin PingCollege of Materials Science and Engineering, Zhejiang University of Technology, Hangzhou, 310014, People's Republic of China.
Dahai LiuDepartment of Vascular Surgery, China-Japan Union Hospital, Jilin University, Changchun, 130033, People's Republic of China. dahai@jlu.edu.cn.

Funding

China Postdoctoral Science Foundation 2023M733360National Natural Science Foundation of China 22305220Natural Science Foundation of Jilin Province JJKH20221056KJ
6 · The paper itself

Abstract

Different from most of the conventional platforms with dissatisfactory theranostic capabilities, supramolecular nanotheranostic systems have unparalleled advantages via the artful combination of supramolecular chemistry and nanotechnology. Benefiting from the tunable stimuli-responsiveness and compatible hierarchical organization, host-guest interactions have developed into the most popular mainstay for constructing supramolecular nanoplatforms. Characterized by the strong and diverse complexation property, cucurbit[8]uril (CB[8]) shows great potential as important building blocks for supramolecular theranostic systems. In this review, we summarize the recent progress of CB[8]-based supramolecular theranostics regarding the design, manufacture and theranostic mechanism. Meanwhile, the current limitations and corresponding reasonable solutions as well as the potential future development are also discussed.

Indexed as

Bridged-Ring CompoundsImidazolesTheranostic NanomedicineAnimalsCucurbit(n)urilsHeterocyclic Compounds, 2-RingHumansImidazolidinesMacrocyclic CompoundsNanoparticlesBridged-Ring Compoundscucurbit(8)urilCucurbit(n)urilsHeterocyclic Compounds, 2-RingImidazolesImidazolidinesMacrocyclic CompoundsCucurbit[8]urilHost–guest reactionsSelf-assemblySupramolecular nanomedicineSupramolecular theranostics

Identifiers

PMID38725031
PMCPMC11084038

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.